Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey

By Monk Bradley J.   Lammers Philip E.   Cartwright Thomas   Jacobs Ira  

Pharmaceuticals, Vol. 10, Iss. 1, 2017-01 ,pp. : 19-19

MDPI

Access to resources Recommend Favorite

Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer

By Li Jianzong   Wang Haiyang   Li Junjie   Bao Jinku   Wu Chuanfang  

International Journal of Molecular Sciences, Vol. 17, Iss. 7, 2016-07 ,pp. : 1055-1055

MDPI

Access to resources Recommend Favorite

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

By Baer William H.   Maini Archana   Jacobs Ira  

Pharmaceuticals, Vol. 7, Iss. 5, 2014-05 ,pp. : 530-544

MDPI

Access to resources Recommend Favorite

HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells

By Yamaguchi Haruka   Hayama Kazuhide   Sasagawa Ichiro   Okada Yasuo   Kawase Tomoyuki   Tsubokawa Norio   Tsuchimochi Makoto  

International Journal of Molecular Sciences, Vol. 19, Iss. 3, 2018-03 ,pp. : 908-908

MDPI

Access to resources Recommend Favorite

Pre-Clinical Assessment of ¹⁷⁷Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease

By Ray Geoffrey L.   Baidoo Kwamena E.   Keller Lanea M. M.   Albert Paul S.   Brechbiel Martin W.   Milenic Diane E.  

Pharmaceuticals, Vol. 5, Iss. 1, 2011-12 ,pp. : 1-15

MDPI

Access to resources Recommend Favorite